Comparison of clinical efficacy between twice-daily formoterol/budesonide combinations and once-daily fluticasone furoate/vilanterol in bronchial asthma

Comparison of clinical efficacy between twice-daily formoterol/budesonide combinations and once-daily fluticasone furoate/vilanterol in bronchial asthma - Comparison of clinical efficacy between formoterol/budesonide and fluticasone furoate/vilanterol in asthma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015609

Enrollment

Registered

2014-11-05

Start date

2014-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Flticasone Frate/Vilanterol (100/25 ug) once daily Two actautions of formoterol/budesonide combinations (160/4.5 ug) twice-daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with asthma whose disease was classified as "controlled" according to the GINA criteria of asthma control under the treatment of two actuations of formoterol/budesonide combinations (160/4.5 ug) twice-daily.

Exclusion criteria

Exclusion criteria: (1) treatment with oral or intravenous corticosteroids in the previous 4weeks, or (2) other pulmonary diseases, including chronic obstructive pulmonary disease.

Design outcomes

Primary

Measure	Time frame
Change from baseline (0 week) in FEV1 after 8 weeks of treatment	—

Secondary

Measure	Time frame
Secondly end points are change in QOL (ACT score, ACQ score), fractional exhaled nitric oxide, forced oscillation technique and adherence after 8 weeks of treatment from baseline (0 week). Adverse events are reported throughout the study	—

Countries

Japan

Contacts

Public ContactTomoyuki Fujisawa

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

fujisawa@hama-med.ac.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026